Nkarta, Inc. (NKTX) Income Statement Analysis

See more : Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) Income Statement Analysis – Financial Results

Complete financial analysis of Nkarta, Inc. (NKTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nkarta, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Nkarta, Inc. (NKTX)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.nkartatx.com

About Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Metric	2023	2022	2021	2020	2019	2018
Revenue	0.00	0.00	0.00	0.00	115.39K	6.55M
Cost of Revenue	5.87M	6.57M	2.12M	1.05M	17.22K	4.25M
Gross Profit	-5.87M	-6.57M	-2.12M	-1.05M	98.17K	2.30M
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	85.08%	35.08%
Research & Development	96.77M	90.90M	63.41M	36.22M	17.22M	4.25M
General & Administrative	34.88M	28.06M	23.02M	15.29M	5.25M	2.65M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	34.88M	28.06M	23.02M	15.29M	5.25M	2.65M
Other Expenses	0.00	-470.00K	-16.00K	-40.17M	1.34M	0.00
Operating Expenses	131.65M	118.96M	86.43M	51.51M	22.46M	6.91M
Cost & Expenses	131.65M	118.96M	86.43M	51.51M	22.46M	6.91M
Interest Income	14.11M	5.59M	370.00K	313.00K	304.11K	81.95K
Interest Expense	0.00	5.59M	0.00	0.00	472.82K	0.00
Depreciation & Amortization	5.87M	6.57M	2.12M	1.05M	553.28K	183.21K
EBITDA	-120.48M	-107.27M	-83.95M	-90.31M	-20.05M	-91.29K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	-17,600.68%	-1.39%
Operating Income	-131.65M	-118.96M	-86.43M	-51.51M	-22.35M	-356.45K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	-19,368.66%	-5.44%
Total Other Income/Expenses	14.15M	5.12M	354.00K	-39.85M	1.27M	81.95K
Income Before Tax	-117.50M	-113.84M	-86.08M	-91.36M	-21.08M	-274.50K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	-18,265.66%	-4.19%
Income Tax Expense	0.00	5.59M	-2.13M	-40.95M	1.81M	81.95K
Net Income	-117.50M	-119.43M	-83.95M	-50.41M	-22.88M	-274.50K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	-19,832.65%	-4.19%
EPS	-2.40	-2.74	-2.55	-1.59	-2.55	0.00
EPS Diluted	-2.40	-2.74	-2.55	-1.59	-2.55	0.00
Weighted Avg Shares Out	49.01M	43.63M	32.86M	31.80M	8.98M	5.03B
Weighted Avg Shares Out (Dil)	49.01M	43.63M	32.86M	31.80M	8.98M	5.03B

Why Shares of Nkarta Are Slumping Tuesday

June 27, 2023fool.com

Nkarta's lead therapy showed limited effectiveness in treating acute myeloid leukemia. Last week, there was a rash of insider selling by company executives.

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

June 26, 2023globenewswire.com

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, June 27, 2023 at 8:00...

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023globenewswire.com

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will present preliminary data from its Phase 1 dose escalation clinical trial...

7 Stocks With Promising Upside Potential for 100% Returns

May 7, 2023investorplace.com

While your friendly financial advisor will probably never recommend these terribly risky enterprises, sometimes, you're just in the mood for stocks with 100% upside potential. And with these ideas, you're going to get that and more, assuming the stars align...

Nkarta to Participate at Upcoming Investor Conferences

April 12, 2023globenewswire.com

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences:

3 Biotech Stocks to Watch for Potential Breakthroughs

April 11, 2023investorplace.com

Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory processes and long development times result in substantial costs.

Nkarta: Going Down Despite Solid Data Due To Fate's Debacle

March 26, 2023seekingalpha.com

NKTX has consistently produced solid data from its NK cell programs. Despite that, the stock is going down.

Nkarta to Participate at Upcoming Investor Conferences

February 9, 2023globenewswire.com

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences: